

Comment on: Pancreatectomy With Islet-Autotransplantation As Alternative for Pancreatoduodenectomy in Patients With a High-Risk for Postoperative Pancreatic Fistula: The Jury Is Still Out

Thomas F. Stoop, MD,*†‡ Poya Ghorbani, MD, PhD,‡ Rutger T. Theijse, BSc.*†
Charlotte L. van Veldhuisen, MD,*† J. Hans DeVries, MD, PhD,§|| Bas Groot Koerkamp, MD, PhD,¶
Hjalmar C. van Santvoort, MD, PhD,# I. Quintus Molenaar, MD, PhD,# Olivier R. Busch, MD, PhD,*†
Marco Del Chiaro, MD, PhD,** and Marc G. Besselink, MD, PhD*†

We would like to congratulate Balzano et al¹ on their randomized controlled bicenter PAN-IT trial wherein total pancreatectomy (TP) with islet-autotransplantation (IAT) was studied as an alternative for patients undergoing pancreatoduodenectomy (PD) with a high-risk for developing postoperative pancreatic fistula (POPF). However, we have some concerns regarding the authors' final conclusions that TP-IAT may become the standard treatment in candidates for PD with a high risk for POPF. Our concerns center on (1) the primary endpoint of the PAN-IT trial, (2) the lack of assessment of patient-reported outcomes, and (3) the quality of diabetes control.

First, it is questionable if postoperative morbidity is the optimal endpoint in a trial that aims to elucidate the role of TP(-IAT) as alternative to PD with a high risk for POPF. How much morbidity should be prevented to justify a lifelong

pancreatic state? Indeed, TP-IAT improved the primary endpoint (ie, 90-day overall complication rate) by avoiding POPF, but the 90-day mortality did not differ statistically significant despite a clinically relevant difference (9.7% after PD vs 3.3% after TP-IAT), which is line with recent retrospective single-center series.^{2,3} However, the mortality after TP(-IAT) in the daily clinical practice may be substantially higher. A recent prospective European international multicenter study including 277 patients who underwent TP found a 90-day mortality rate of 7.6%, which increased to even 11.9% in centers performing less than 60 PDs per year.⁴ Moreover, the recent Dutch PORSCH trial demonstrated that postoperative mortality can be reduced after PD regardless of hospital volume due to the implementation of an algorithm for early detection and treatment of POPF.⁵ As a consequence, the vast majority of the clinically relevant POPF can be managed either conservatively or with minimally invasive interventions.⁵

Second, patient-reported outcomes including quality of life over time are highly relevant endpoints when determining the role of TP(-IAT) in our opinion. Surprisingly, quality of life was not evaluated over time, while the prospective nature of the PAN-IT trial offered a unique opportunity to investigate this properly. This should be included in future prospective studies. Although the interest in TP for this indication has been renewed in recent years by the improved morbidity and mortality after TP in high-volume centers^{4,6} and more adequate management of the associated metabolic insufficiencies, the related adverse events remain substantial.⁷ Quality of life on the middle- and long-term after TP is reduced in comparison to the general population.^{8,9} IAT after TP only (mostly temporarily) controls the endocrine insufficiency partially, whereas exocrine insufficiency remains a challenge. This is especially relevant for the currently studied indication of TP(-IAT) since patients with a high risk for POPF after PD often have long-term survival because of benign/ premalignant pancreatic diseases.

Third, the quality of diabetes control and insulin independence obtained by TP-IAT. Already after 1 month, glycemic control as measured by hemoglobin A1c was worse in the TP-IAT group and at the end of follow-up (median follow-up of 388 days), only 6.7% of patients after TP-IAT were independent of insulin versus 80.6% of patients after high-risk PD. The authors argue that the absence of serious hypoglycemic events is explained by the remaining graft function. However, long-term results are missing, while these are highly important considering the likelihood that the graft function will further decrease over time. An alternative for or additive to IAT might be the bihormonal artificial pancreas, for which we recently demonstrating promising results.¹⁰

In summary, the PAN-IT is a high quality randomized trial that provides quite relevant insights, but in our opinion does

From the *Amsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam, The Netherlands; †Cancer Center Amsterdam, Amsterdam, The Netherlands; ‡Division of Surgery, Department of Clinical Science, Intervention and Technology, Karolinska Institutet at Karolinska University Hospital, Stockholm, Sweden; §Amsterdam UMC, location University of Amsterdam, Department of Internal Medicine, Amsterdam, The Netherlands, Amsterdam, The Netherlands; ||Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam, The Netherlands; ¶Department of Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands; #Department of Surgery, Regional Academic Cancer Center Utrecht, University Medical Center Utrecht/St. Antonius Hospital Nieuwegein, Utrecht/Nieuwegein, The Netherlands; and **Division of Surgical Oncology, Department of Surgery, University of Colorado Denver Anschutz Medical Campus, Aurora, CO, United States.

Disclosure: M.D.C. has been awarded with an industry grant (Haemonetics, Inc) to conduct a multicenter study to evaluate the prognostic implications of thromboelastography in pancreatic cancer. M.D.C. is co-principal investigator of a Boston Scientific-sponsored international multicenter study on the use of intraoperative pancreatoscopy of patients with intraductal papillary mucinous neoplasm. The other authors declare that they have nothing to disclose.

Reprints: Marc G. Besselink, MD, PhD, Department of Surgery Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, De Boelelaan 1117 (ZH-7F), 1081 HV Amsterdam, The Netherlands. Email: m.g.besselink@amsterdamUMC.nl.

Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Annals of Surgery Open (2023) 1:e247

Received: 27 October 2022; Accepted 4 November 2022

Published online 30 January 2023

DOI: 10.1097/AS9.000000000000247

not confirm that TP-IAT may become the standard treatment in patients with a high risk for POPF after PD. We question whether a 30% absolute risk reduction of short-term post-operative morbidity justifies a 73% absolute risk increase of lifelong insulin dependence and, most likely, decreased quality of life. Furthermore, early POPF recognition and step-wise minimally invasive management have an important role in the improvement of both morbidity and mortality after PD. Only future large, randomized studies with mortality and quality of life as primary outcome can answer this question.

REFERENCES

- Balzano G, Zerbi A, Aleotti F, et al. Total pancreatectomy with islet autotransplantation as an alternative to high-risk pancreatojejunostomy after pancreaticoduodenectomy: a prospective randomized controlled trial [published online ahead of print September 30, 2022]. *Ann Surg*. doi: 10.1097/SLA.0000000000005713.
- Marchegiani G, Perri G, Burelli A, et al. High-risk pancreatic anastomosis vs. total pancreatectomy after pancreatoduodenectomy. *Ann Surg*. 2022;276:e905–e913.
- Stoop TF, Ghorbani P, Scholten L, et al. Total pancreatectomy as an alternative to high-risk pancreatojejunostomy after pancreatoduodenectomy: a propensity score analysis on surgical outcome and quality of life. *HPB (Oxford)*. 2022;24:1261–1270.
- Latenstein AEJ, Scholten L, Al-Saffar HA, et al. Clinical outcomes after total pancreatectomy: a prospective multicenter pan-European snapshot study. *Ann Surg*. 2022;276:e536–e543.
- Smits FJ, Henry AC, Besselink MG, et al. Algorithm-based care versus usual care for the early recognition and management of complications after pancreatic resection in the Netherlands: an open-label, nationwide, stepped-wedge cluster-randomised trial. *Lancet*. 2022;399:1867–1875.
- Stoop TF, Ateeb Z, Ghorbani P, et al. Surgical outcomes after total pancreatectomy: a high-volume center experience. *Ann Surg Oncol*. 2021;28:1543–1551.
- Scholten L, Stoop TF, Del Chiaro M, et al. Systematic review of functional outcome and quality of life after total pancreatectomy. *Br J Surg*. 2019;106:1735–1746.
- Scholten L, Latenstein AEJ, van Eijck C, et al. Outcome and long-term quality of life after total pancreatectomy (PANORAMA): a nationwide cohort study. *Surgery*. 2019;166:1017–1026.
- Stoop TF, Ateeb Z, Ghorbani P, et al. Impact of endocrine and exocrine insufficiency on quality of life after total pancreatectomy. *Ann Surg Oncol*. 2020;27:587–596.
- van Veldhuisen CL, Latenstein AEJ, Blauw H, et al. Bihormonal artificial pancreas with closed-loop glucose control vs current diabetes care after total pancreatectomy: a randomized controlled clinical trial. *JAMA Surg*. 2022;157:950–957.